Full Breakdown
Public Health Groups Sue EPA Over Isocycloseram Approval
1/24/2026, 9:41:47 PM
Lawsuit Against the EPA
Public health organizations, including the Center for Biological Diversity, have initiated a lawsuit against the Environmental Protection Agency (EPA) regarding its approval of the pesticide isocycloseram. This chemical, categorized as a "forever chemical," has been linked to adverse health effects, including reduced testicle size and lower sperm counts in rats, as well as liver damage. The lawsuit asserts that the EPA failed to adequately consider the risks posed to children and developing fetuses during its safety assessment of the pesticide, which is used on a variety of food crops such as apples, oranges, and tomatoes.
Background on Isocycloseram and PFAS
Isocycloseram is part of a broader class of chemicals known as per- and polyfluoroalkyl substances (PFAS), which are notorious for their persistence in the environment and potential health risks. The EPA's approval of isocycloseram has reignited debates over the use of PFAS in pesticides, particularly as public health advocates have raised concerns about the chemical's long-term effects. Critics argue that the agency's decision reflects a troubling trend of prioritizing corporate interests over public health, especially given the involvement of former industry lobbyists in the EPA's chemical safety office.
Criticism of EPA's Risk Assessment
Critics, including Nathan Donley from the Center for Biological Diversity, have highlighted significant flaws in the EPA's risk assessment process. They argue that the agency's reliance on industry-funded research has led to a lack of independent review and inadequate consideration of cumulative exposure risks. Donley emphasized that the EPA's assessment did not account for the potential impact of isocycloseram on over 1,000 threatened and endangered species, nor did it consider the chemical's toxicity to pollinators.
Kelly Ryerson, an advocate with the Make America Healthy Again (Maha) movement, criticized the EPA for its approval of isocycloseram, stating that it undermines public health and reflects a disconnect between the agency's leadership and the concerns of the public. Ryerson expressed concern that the decision-making process at the EPA is heavily influenced by pesticide industry interests.
Official Statements
In response to the lawsuit, an EPA spokesperson stated that the agency does not comment on ongoing litigation but reiterated its commitment to addressing PFAS and protecting children's health. The spokesperson claimed that the EPA is dedicated to using "gold-standard science" to fulfill its mission of safeguarding human health and the environment.
Conflicting Reports & Gaps
The approval of isocycloseram has drawn scrutiny not only for its health implications but also for the EPA's overall approach to chemical regulation. Critics argue that the agency's risk assessment process is flawed and lacks transparency, raising questions about the adequacy of safety measures in place for pesticides containing PFAS. Additionally, there are discrepancies regarding the extent of the chemical's environmental persistence and its potential effects on wildlife.
What's Next
The lawsuit against the EPA is part of a larger trend of legal challenges aimed at holding the agency accountable for its regulatory decisions. As public health groups continue to advocate for stricter oversight of pesticides and chemicals, the outcome of this case could have significant implications for future regulatory practices and public health protections.
